Drug
Ak139
Ak139: highest development phase Phase 2, developed by Akeso. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK139 NCT07502222 | Phase 2 | Moderate-to-Severe Atopic Dermatitis |
| AK139 NCT07883213 | Phase 2 | Prurigo Nodularis (PN) |
| AK139 NCT07875426 | Phase 2 | Chronic Spontaneous Urticaria |
| AK139 NCT07755371 | Phase 2 | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) |
Latest
No recent events.
Follow Ak139 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.